Aspirin is essentially subjectively silent at therapeutic doses. The drug works without producing any noticeable subjective state. Users:

• Feel no acute "kick" or alteration in mental state.
• May notice stomach discomfort or heartburn within 30-60 min of dosing on an empty stomach (acidic salicylate is locally irritating to gastric mucosa).
• May notice tinnitus at high doses (>2-3 g/day) — this is an early sign of salicylate accumulation and is one of the body's reliable internal early-warning signs of aspirin toxicity.
• Experience no euphoria, alertness change, sleep change, or cognitive change at any normal dose.

The lack of subjective signal is part of why aspirin is dangerous when overused: there is no "I've had enough" feeling. People can take chronic high doses for arthritis pain and develop slow GI bleeding without realizing it.

Onset: 30-60 min for analgesic/antipyretic effect (immediate-release tablets); ~3-4 hours for enteric-coated formulations. Antiplatelet effect onset: within minutes of swallowing chewable tablets, ~30-45 min for swallowed tablets.

Half-life: Acetylsalicylic acid (parent drug) ~15-20 min; salicylate metabolite ~3-6 hours at low doses, longer at high doses (Michaelis-Menten saturation).

• No pharmacological tolerance. COX inhibition is mechanism-based; the enzyme is dead and replaced. Each new dose acetylates a fresh population.
• Platelet-level "tolerance" is functionally non-existent at therapeutic doses — once steady-state platelet COX-1 acetylation is achieved (~1 week of daily 81 mg), aggregation is suppressed continuously.
• Cycling is not a meaningful concept for aspirin. The drug is either taken (suppressing platelet/COX-2 activity) or not. There is no benefit to weekly off-days at low dose; the platelet pool needs ~10 days to fully regenerate function once stopped.

Synergistic with (in clinical practice — not relevant for this user profile)

• Statins (atorvastatin, rosuvastatin) — secondary CV prevention combination is standard. No PD interaction.
• Clopidogrel — dual antiplatelet therapy (DAPT) for post-stent/post-ACS. Markedly raises bleed risk.
• ACE inhibitors / ARBs — secondary prevention combinations common; mild renal interaction concern.
• Beta-blockers — secondary prevention combinations standard.

Avoid stacking with

• Other NSAIDs (ibuprofen, naproxen, ketoprofen, diclofenac) — reversible NSAIDs compete with aspirin for COX-1 binding and can prevent the irreversible acetylation if dosed before aspirin, blunting cardioprotection. And the combined drug exposure raises GI bleed risk multiplicatively. Avoid daily NSAID + aspirin combinations unless specifically managed (typically by separating doses by ≥30 min, with aspirin first).
• Anticoagulants (warfarin, DOACs, heparin, LMWH) — bleeding risk multiplies. Combinations used clinically (e.g., warfarin + aspirin in some valve patients) but with explicit risk acceptance and tight monitoring.
• Corticosteroids (prednisone, dexamethasone chronic) — additive GI ulcer risk. Standard practice to add PPI for gastroprotection if combined.
• SSRIs (chronic) — modest antiplatelet effect of SSRIs (via serotonin-mediated platelet activation suppression) compounds aspirin's effect; small but real GI/bleed risk increase. Particularly relevant for fluoxetine, sertraline, paroxetine.
• High-dose fish oil / EPA-DHA (>3 g/day) — modest antiplatelet contribution; theoretical bleed risk amplification. Magnitude small but worth flagging.
• Ginkgo biloba — antiplatelet effect; case reports of bleeding when combined with aspirin.
• Nattokinase, lumbrokinase, serrapeptase — fibrinolytic/proteolytic supplements; theoretical bleed risk amplification.
• High-dose curcumin (>1 g/day, especially highly-bioavailable formulations) — mild antiplatelet effect; theoretical concern.
• Alcohol (heavy) — additive GI ulceration risk.
• Methotrexate — aspirin reduces MTX clearance, raises MTX toxicity. Avoid in chronic rheumatology dosing.
• Probenecid / sulfinpyrazone (uricosurics) — aspirin antagonizes their effect.
• ACE inhibitors + diuretics ("triple whammy" when adding NSAID/aspirin) — acute kidney injury risk in dehydrated/elderly patients.

Neutral / safe co-administration

• Most basic supplements (creatine, multivitamin, magnesium, vitamin D3, electrolytes, protein powder) — no PK/PD interaction.
• Caffeine — neutral.
• Low-dose fish oil (1-2 g/day) — minimal additional bleed risk.

Beyond stacking concerns above, key clinical drug interactions:

• Ibuprofen specific: dose ibuprofen ≥30 minutes after aspirin (or ≥8 hours before) to avoid blocking aspirin's irreversible COX-1 acetylation. This is an FDA-flagged interaction with specific labeling.
• Naproxen: less potent COX-1 reversible binding than ibuprofen, less interference with aspirin acetylation, but still some.
• Celecoxib: COX-2 selective, doesn't compete for COX-1 binding; cleaner stack with aspirin from a PD standpoint, though still cumulative GI risk.
• Methotrexate: aspirin decreases MTX renal clearance via OAT competition; raises MTX serum level into potentially toxic range in chronic rheumatology dosing.
• Probenecid / sulfinpyrazone: aspirin reduces uricosuric effect (competes for renal tubular secretion).
• ACE inhibitors / ARBs: aspirin partially blunts the prostaglandin-mediated component of antihypertensive effect; clinically modest at low aspirin doses (81 mg) but more relevant at higher doses.
• Spironolactone: aspirin antagonizes the natriuretic effect of spironolactone via PGE2 suppression in the distal nephron.
• Antiepileptics (valproic acid, phenytoin): aspirin can displace these from albumin binding at high doses, raising free fraction.
• Sulfonylureas (glyburide, glipizide): salicylate displacement from albumin + intrinsic hypoglycemic effect of high-dose salicylate; clinically relevant in elderly diabetics on aspirin + sulfonylurea.

• PEAR1 (rs12041331) — variants associated with platelet response heterogeneity to aspirin. About 20-30% of aspirin users show "aspirin resistance" (incomplete platelet TXA2 suppression on standard 81 mg dose), with PEAR1 polymorphism contributing modestly.
• GPIIIa PlA1/A2 polymorphism (rs5918 in ITGB3) — A2 carriers may have altered platelet aggregation phenotype, modest interaction with aspirin response.
• CYP2C9 — minor role in aspirin metabolism; high-affinity glucuronidation is the dominant clearance pathway.
• UGT1A6 — major role in salicylate glucuronidation. UGT1A6*2/*2 homozygotes have reduced salicylate clearance, theoretical risk for high-dose toxicity.
• 23andMe-derivable: PEAR1, GPIIIa, UGT1A6 variants are inferable from raw data. Not currently a routine input for aspirin therapy decisions but increasingly relevant in cardiology pharmacogenomics research.

For this user: trivially available if ever needed for legitimate indication (acute analgesic, fever, suspected MI). No sourcing concern.

If ever started chronically (not relevant for this user currently)

• Resting BP + HR — baseline and quarterly.
• Lipid panel + ApoB — annual; aspirin's value is in CV risk context.
• hsCRP — baseline; may decrease modestly on aspirin (anti-inflammatory).
• CBC (hemoglobin, hematocrit, platelet count) — every 6-12 months to detect occult GI bleed.
• Fecal occult blood / fecal immunochemical test (FIT) — annual; primary screen for GI blood loss.
• eGFR, creatinine — annual; rule out NSAID nephrotoxicity.
• GI symptom log — heartburn, epigastric pain, melena, hematemesis. Threshold for stopping should be low.
• INR (if on warfarin) — when adding aspirin; baseline + frequent retesting.

Watch periods

• First 1-3 months: GI symptoms, bruising. If significant, reconsider.
• Year 1+: Annual occult blood + Hgb. Cumulative bleed risk.
• Any new medication added: check for interaction. Particularly NSAIDs, anticoagulants, SSRIs.